JAK2 and neoplasm: Interestingly, in the presence of fedratinib and CHZ868, CD19 CAR-T cells maintained their anti-tumor function even in the multiple rounds of tumor rechallenge, including JAK2 wild-type REH cells (Fig. 2c, Supplementary Fig. 3b).